News

Highly Acclaimed Dystel Prize awarded to Professor Thompson

1 May 2017

The American Academy of Neurology have awarded the prestigious John Dystel Prize for Multiple Sclerosis Research to the well deserving Professor Alan Thompson. Professor Thompson is a driving force within the International Progressive MS Alliance, which is an unprecedented global collaboration of MS organisations (including MS Research Australia), researchers, clinicians, pharmaceutical companies and people with progressive MS, dedicated in their goal to change the landscape of MS.

Professor Thompson is currently Dean of the University College London Faculty of Brain Sciences. He was chosen by a committee of his peers to receive the prestigious prize worth $15,000 given jointly by the National MS Society and the American Academy of Neurology.

Spending the last 35 years of his life focusing on the care and treatment of people with MS, Professor Thompson has shown both his dedication and perseverance to improve the quality of life for people living with MS. Some examples of his valuable work include: the usage of MRI’s to determine the criteria for diagnosis of MS, pioneering symptom-related outcome measures in MS research, evaluating cannabinoids to treat MS and finally, spearheading and acting as Chair of the Scientific Steering Committee of the International Progressive MS Alliance.

We at MS Research Australia are very proud of our involvement with Professor Thompson and congratulate him on this well-deserved prize.

Related News

Media Release

Early results show world-first adaptive trial in action for progressive MS

17 September 2026

A potential treatment for progressive multiple sclerosis (MS) will continue in a world-first multi-arm, multi-stage adaptive trial after showing encouraging early signs, with recruitment set to expand across Australia.

MS News

Alpha lipoic acid shows promise in Stage 1 of Octopus trial in progressive MS

17 September 2026

Results from Stage 1 of the Octopus trial find one of the trial treatments, alpha lipoic acid, shows promise in progressive MS and will continue into trial Stage 2.

MS News

Women and MS: one of the disease’s biggest mysteries

9 September 2026

Why does MS affect women more often than men? How does female biology impact MS activity? Discover what recent research is revealing about risk, hormones, immunity and EBV.

Read More

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

Highly Acclaimed Dystel Prize awarded to Professor Thompson